# A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)

> **NCT02336230** · PHASE3 · COMPLETED · sponsor: **Mesoblast, Inc.** · enrollment: 55 (actual)

## Conditions studied

- Grade B aGVHD
- Grade C aGVHD
- Grade D aGVHD

## Interventions

- **DRUG:** remestemcel-L

## Key facts

- **NCT ID:** NCT02336230
- **Lead sponsor:** Mesoblast, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-04
- **Primary completion:** 2018-04-09
- **Final completion:** 2018-04-09
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2022-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02336230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02336230, "A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT02336230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*